Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PowderMed Ltd.

Division of Pfizer Inc.
www.powdermed.com

Latest From PowderMed Ltd.

Appointments: Almirall, Axial, Therachon, Theranexus, Carrick and Karolinksa

This week's roundup includes Almirall's appointment of a former Sanofi employee as CEO and various other high-level appointments by Axial, Therachon, Theranexus and Karolinska.

Appointments BioPharmaceutical

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007

We present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for October-December 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
BioPharmaceutical

Orphaning Biotech? The Impact of Biosimilars on Biotech Investment

An abbreviated follow-on biologics pathway is inevitable, despite the fact that Congress failed to pass legislation in 2007. Will a FOBs pathway adversely impact money flowing into the biotech industry? Unlikely. The impact of the 1983 Orphan Drug Act may be a good model to consider. (This article first appeared in the RPM Report, January 2008).
BioPharmaceutical Platform Technologies

NasVax Ltd.

NasVax Ltd.'s VaxiSome, a novel adjuvant/delivery system for enhacing the activity of existing vaccines, consists of lipid assemblies comprising an innovative, proprietary family of positively charged polycationic lipids. The technology generates strong adjuvant activity, with the potential for intranasal, intramuscular, or subcutaneous administration. This platform can also be applied to boost the bioactivity of various immunomodulators, such as a broad spectrum of well-established adjuvants and cytokines.
BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • PowderJect Pharmaceuticals PLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Clive Dix, CEO
    John Beadle, CMO
    Adam Christie, CBO
  • Contact Info
  • PowderMed Ltd.
    Phone: (44) 01865 501500
    PO Box 1415
    Oxford, OX4 4ZZ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register